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ABSTRACT
Introduction:
Hepatitis C Virus (HCV) Infection is the most common blood-borne infection in the world with a
global prevalence of ~3%. It also represents an underestimated and under-recognized viral
infection because it is asymptomatic during the initial period of infection, which tends to span
several decades. However, after establishing itself as a chronic state, HCV infection often leads
to severe debilitating liver conditions such as cirrhosis, hepatocellular carcinoma to name a few
resulting in poor quality of life, increased healthcare costs and mortality. Several earlier studies
have examined risk factors associated with HCV. However, a comprehensive study that has
simultaneously evaluated a wide range of addictive risk behaviors associated with HCV has not
been conducted to date. This type of investigation will help to identify at-risk populations for
HCV and provide valuable information regarding how one might efficiently link them to
appropriate treatment and care.
Aim:
The primary aims of this study were 1). To estimate chronic HCV infection (CHI) prevalence in
non-institutionalized U.S. adult population from 2003-2014 2). To perform a multivariate
examination of all known behavioral risk factors significantly associated with CHI and 3). To
identify less invasive questions regarding risk behaviors associated with CHI that could be used
to predict state-level CHI prevalence using other state-specific data sources such as The
Behavioral Risk Factor Surveillance System (BRFSS).
Methods:
The study utilized nationally representative data from National Health and Nutrition
Examination Survey (NHANES) for the years 2003-2014. HCV RNA positive persons were CHI
positive population. Bivariate analyses were performed to examine the frequency distributions
of the study’s primary dependent variable (CHI) and all independent variables (demographical +
behavioral risk factor variables). The analysis sample included 11,596 adults aged 20-59 years.
Risk factors for CHI were examined using both bivariate and multivariate logistic regression
analyses. We first conducted weighted bivariate logistic regression analyses to examine the
10

relationships of dependent and independent variables without controlling for potential
confounders. We then conducted weighted multivariate adjusted logistic regression analyses to
examine the relationships between the dependent and independent variables while controlling
for potential confounders. Odds ratios (OR), 95% confidence limits (CL) and p-values were
calculated. A p-value < 0.05 was considered statistically significant. SAS 9.4 was used for all
statistical analyses.
Results:
The estimated number of CHI adults aged >/= 20 years in 2014 was 1.93 million leading to an
estimated CHI prevalence of 0.7%. Injection drug users (IDU) had the highest CHI prevalence of
30.24% by bivariate analyses. Multivariate logistic regression analysis in the chronic HCV full
model indicated that age categories 40-49 y (OR: 7.9, 95% CL: 3.8-16.2) and 50-59 y (OR: 8.0,
95% CL: 3.5-18.2); non-Hispanic blacks (OR: 2.4, 95% CL: 1.3-4.1); less than high school
education (OR: 2.6, 95% CL: 1.5-4.8); < 2.0 times the poverty level (OR: 3.5, 95% CL: 1.9- 6.6);
heroin consumers (OR: 2.3, 95% CL: 1.1-4.6); IDU (OR: 8.1, 95% CL: 3.1-21); blood transfusion
recipients (OR: 2.9, 95% CL: 1.4-5.7) and >/= 10 lifetime sex-partners (OR: 5.5, 95% CL: 1.5-19.7)
were significantly associated with CHI.
Multivariate logistic regression analysis in the chronic HCV risk factor model indicated that
persons in moderate (OR: 2.5, 95% CL: 1.1-5.5) and high (OR: 30.3, 95% CL: 12.1-76) substance
abuse risk factor categories were significantly associated with CHI. Multivariate logistic
regression analysis in chronic HCV BRFSS model indicated that age categories 40-49 y (OR: 7.5,
95% CL: 3.5-15.9) 50-59 y (OR: 8.7, 95% CL: 4.2-18); males (OR: 3.1, 95% CL: 1.5-6.4); nonHispanic black (OR: 1.8, 95% CL: 1.1-2.9); less than high school education (OR: 2.2, 95%CL: 1.33.8); < 2.0 times the poverty level (OR: 3.7, 95% CL: 2.0-6.8); alcohol consumers (OR: 1.7; 95%
CL: 1.0-2.9) and smokers (OR: 3.7, 95% CL: 1.8-7.6) were significantly associated with CHI. cstatistic of the three models were 0.94, 0.92 and 0.88 respectively thereby implying that all
three models were strong models with a higher predictive accuracy of CHI.
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Conclusions:
We conclude that the estimated prevalence of CHI in this analysis sample is 0.7%, however the
true prevalence estimates of CHI are likely to be significantly higher if incarcerated, homeless
and other population not presented in NHANES are included. IDU continues to be the strongest
risk factor for CHI. Persons with two or more addictive behavioral risk factors have significant
associations with CHI. Results from this study will enable identification of at-risk population for
CHI and provide valuable information for linking them to appropriate treatment and care.
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CHAPTER ONE
INTRODUCTION
1.1 Background
Hepatitis C virus (HCV) infection is the most common blood-borne infection worldwide. In
1989, Choo et al (1) successfully cloned a single cDNA clone derived from a new flavi-like virus
by various molecular biological methods. This virus was responsible for most post-transfusion
hepatitis, also called type C hepatitis, parenterally transmitted non-A non-B hepatitis (PTNANB), non-B transfusion-associated hepatitis, post-transfusion non-A non-B hepatitis, and this
virus was identified as HCV (2). Globally, up to 3% of the world’s population, which is about 200
million individuals, are estimated to have HCV infection (3); ~71 million are estimated to have
CHI out of which 400,000 deaths occur due to cirrhosis and hepatocellular carcinoma because
of CHI (World Health Organization Fact Sheet, October 2017). In the civilian noninstitutionalized U.S. population, approximately 2.7 million persons have CHI (4).
HCV infection remains asymptomatic in many persons and approximately half the infected
are unaware of their infection. Within 30 years, 41% of infected persons’ progress to cirrhosis,
hepatocarcinoma and mortality from liver-related causes (5). A majority of the infected do not
receive antiviral treatment because they are unaware of their infection (6). Due to these
reasons, the quality of life (QOL) is negatively affected in the infected population along with
exorbitant health care costs associated with treatment and care of the infected. Therefore, it is
important to identify the at-risk population for HCV infection and direct them to appropriate
treatment and care to positively impact the QOL and decrease the healthcare associated costs.
Anti-HCV positive persons are positive to HCV antibody which indicate prior or current Hepatitis
C virus infection termed as acutely infected population and HCV RNA positive persons indicate
current infection termed as chronically infected population. Chronic HCV infection (CHI) is
developed from acute HCV infection in the affected population.
1.2 Purpose of this study
Denniston et al (4) have conducted a comprehensive study for determination of risk factors
associated with CHI in the US non-institutionalized population between 2003-2010. This is the
most comprehensive study conducted to date where associations between behavioral risk
13

factors and CHI were determined. It would be useful to examine all possible risk factors
associated with CHI to better identify the at-risk populations. It would also be useful to better
characterize the risk associated with CHI by developing summary measures of risk which could
be used in clinic settings and/or in future studies for identification of at-risk individuals for CHI
who should be tested and treated. In addition, it will be helpful to estimate CHI prevalence at
the state or county levels by using predictive models. In this study, we propose to fill these gaps
by conducting a multivariate examination of all possible risk factors of CHI in the noninstitutionalized U.S. adult population using National Health and Nutrition Examination Survey
(NHANES) datasets from 2003-2014.
1.3 Research Questions
Research questions asked in this study are below,
1. Is there an association between age, sex, race/ethnicity, marital status, education and
family income with CHI after adjusting for confounders in the US adult population 20 –
59 years of age?
2. Is there an association between smoking, alcohol consumption, illegal drug use,
injection drug use, blood transfusion and lifetime sex-partners with CHI after adjusting
for confounders in the US adult population 20 – 59 years of age?
3. Does the odds of CHI increase with increasing number of substance abuse risk factors in
the US adult population 20 – 59 years of age?
4. Can the risk for CHI in the US adult population 20 – 59 years of age be modeled without
sensitive behavioral information regarding risk factors such as illegal drug use or number
of sexual partners so that predictive models of CHI prevalence could be developed from
other data sources that do not include such sensitive behavioral information?
1.4 Hypotheses
Our hypotheses are,
1. One or more of the demographical variables in 1.3.1 is significantly associated with CHI
by adjusted multivariate analysis.
2. One or more of the behavioral risk factors and/or blood transfusion in 1.3.2 is
significantly associated with CHI by adjusted multivariate analysis.
14

3. Prevalence and odds of CHI significantly increases with associations with increasing
number of substance abuse risk factors.
1.5 Organization of the thesis
This thesis is organized into five chapters. Chapter one is the Introduction which describes
the background of the study, purpose of this study, research questions and hypotheses.
Chapter two is the Literature Review followed by detailed description of the Methodology in
Chapter three. Chapter four details the Results and Chapter Five is composed of Discussion,
Study Limitations and Conclusions.
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CHAPTER TWO
LITERATURE REVIEW
2.1 Hepatitis C is a liver disease caused by the Hepatitis C virus: biology and pathology
HCV first characterized in 1989 by Choo et al (1) and Kuo et al (7) is an enveloped RNA virus
of the genus Hepacivirus of the family Flaviviridae. Its genome consists of 9.6-kb single-stranded
RNA which codes for a long polyprotein of approximately 3000 amino acids which is processed
post-translationally to yield structural proteins (core and envelope proteins E1, E2) and nonstructural (NS) proteins. The envelope proteins are the outer surface proteins of the viral
particles which play a key role in virus entry into the host cell (8). HCV RNA virus has a high
degree of heterogeneity resulting in six major genotypes and more than 120 subtypes of HCV
(9).
There are three major types of HCV genotypes- genotype 1 (GT1), genotypes 2 and 3 (GT2
and GT3) that influence disease progression and responses to therapy. In the US, GT1 is the
most prevalent as it is affects ~70% of patients while GT2 and GT3 affect ~13% of patients with
HCV.
2.2 Acute and Chronic HCV infection, its comorbidities
Hepatitis C is a contagious liver disease that ranges in severity from a mild illness lasting a
few weeks to a serious, lifelong illness that attacks the liver. Acute Hepatitis C virus infection is
a short-term illness that occurs within the first 6 months after infection with HCV. Acute HCV is
usually asymptomatic and about 15-45% of the infected spontaneously clear the virus by a
strong immune response without any treatment within 6 months of infection. Acute HCV is a
contagious viral infection spread through contact with infected blood and bodily fluids. Chronic
Hepatitis C virus infection is a long-term illness that occurs when the HCV RNA remains in a
person’s body for at least 6 months after viral transmission (10). In 55-85% of the population
that don’t clear the virus after an acute HCV infection, it will develop into a chronic HCV
infection (CHI). The presence of hypervariable regions in the E2 envelope glycoprotein, lack of
proof reading ability, high rate of generating new viral variants during infection, ability to evade
the host immune responses together allow HCV to persist in the infected persons and establish
16

into a CHI (11). In those people who develop CHI, the infection is often undiagnosed because it
remains asymptomatic until decades after infection when symptoms develop and lead to
serious liver problems, including hepatitis, cirrhosis (scarring of the liver) or liver cancer (Figure
1). Persistent HCV infection is accompanied by liver cirrhosis, hepatocellular carcinoma (HCC),
end stage liver disease and finally death (12).
Lu etal (13) carried out The Chronic Hepatitis Cohort Study (CHeCS) that comprised of
11,167 adults with CHI receiving care at one of four large health systems and studied changing
trends in rates of cirrhosis, decompensated cirrhosis and all-cause mortality. Results from this
study showed that prevalence of cirrhosis increased from 20.8% to 27.6% from 2006 to 2015 in
chronic HCV patients. Their study showed that HCV patients >/60 years of age had the highest
prevalence of liver-related complications when compared to younger patients <60 years of age.
Similar findings were published by El- Serag et al (14) from their retrospective cohort study of
161,744 chronic HCV patients in the Veterans Health Administration Hepatitis C Clinical Case
Registry. Persistent HCV infection is accompanied by liver cirrhosis, hepatocellular carcinoma
(HCC), end stage liver disease and finally death (12). Kanwal etal (15) conducted a retrospective
cohort study of approximately 110,000 US veterans with CHI of known HCV genotypes 1, 2, 3,
and 4 from the VA HCV Clinical Case Registry between 2000 and 2009. Results from this study
showed that HCV GT3 was associated with a significantly increased risk of developing cirrhosis
and hepatocarcinoma when compared to genotype 1.
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Figure 1: Natural history of hepatitis C virus infection (16)

2.3 HCV related healthcare costs
The quality-adjusted life year (QALY) is a generic measure of disease burden, which includes
both measures of morbidity (self-reported health) and mortality to assess the quality and
quantity of life, lived. It is used in economic evaluation to assess the value for money of medical
interventions. One QALY is equal to one year in perfect health. In their study, Younossi et al
compared the cost-effectiveness (CE) of three HCV screening strategies for treatment with oral
direct acting antiviral drugs (DAA). The three strategies were screen all (SA), screen Birth Cohort
(BCS), and screen high risks (HRS). SA cost $272.0 billion with 12.19 QALYs per patient, BCS cost
$274.5 billion and led to 11.65 QALYs per patient and HRS cost $284.5 billion with 11.25 QALYs
per patient. This study concluded that screening the entire US population and treating active
viraemia as cost-saving (17).
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Davis et al (18) conducted a case-control study where they analyzed a large United States
claims database (from 1/1/2002 to 12/31/2006) to estimate all-cause and disease-related
resource utilization and costs among managed care enrollees with chronic HCV. Use and costs
of medical services and prescription drugs over a 12-month post-diagnosis period were
determined. Results from this study showed that adjusted all-cause costs were $20,961 per
HCV patient when compared with $5451 per control (p<0.0001). Hospitalization occurred in
24% of HCV patients when compared with 7% of controls (p<0.0001). This study concluded that
disease-related costs in HCV exceeded all-cause costs in demographically matched controls.
Total healthcare cost associated with HCV infection in 2011 was $6.5 ($4.3-$8.2) billion which is
expected to peak in 2024 at $9.1 ($6.4-$13.3) billion (19). Majority of this peak cost will be
attributable to advanced liver diseases such as decompensated cirrhosis (46%), compensated
cirrhosis (20%) and HCC. Hunter et al (20) performed a retrospective study of chronic HCV
patients to determine the relationships between HCV genotypes and liver disease progression,
healthcare resource utilization (HCRU) and healthcare costs. This study showed that patients
with GT1 had the highest total all-cause costs, patients with GT3 had the highest liver-related
comorbidities and patients with GT2 had lower HCRU and the lowest costs. GT3 is associated
with higher risk of liver complications that leads to increased health care cost (21, 22).
In a recent study El Khoury et al (23), estimated the burden of untreated HCV infection in
patients associated with high economic costs and reduced quality of life in comparison with
matched controls. Annual productivity losses of untreated HCV infection patients were
significantly higher when compared with matched controls ($8,209 vs. $4,424, p < 0.001) and
the average total costs were approximately $27,000 per untreated HCV infected patient per
year which was about 150% of the total costs of the matched controls. This study also showed
that untreated HCV infected patients had significantly lower health related quality of life
(HRQoL) than matched controls.
The advent of DAAs has been revolutionary in the advancement of HCV treatment. DAAs
have fewer side effects, shorter duration times (~12 weeks) for treatment, high sustained
virologic response (SVR) and are effective regardless of race and gender. Exorbitant prices of
DAAs serve as a major obstacle to the wide use of these drugs for HCV treatment. Average cost
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per pill is ~$1000 and approximate cost of treatment for 12 weeks is $84,000 (24). However, in
August 2017 Food and Drug Administration (FDA) has approved two new DAAs to treat all
genotypes of HCV. AbbVie’s Mavyret (glecaprevir/pibrentasvir) was approved and launched for
a reduced price of $26,400 for 8 weeks (www.mavyret.com). This lower cost is partly due to its
shorter treatment duration, but even people who need 12 or 16 weeks would still pay less than
they would for existing therapies.
2.4 Estimation of prevalence gives us key information about the scope of the problem
HCV prevalence is highest in Africa and the Middle East ranging from 2 – 15%, whereas
prevalence in North America, Japan, Australia, Northern and Western Europe is the lowest not
>2%. Egypt has the highest HCV prevalence (25, 26). In the United States non-institutionalized
civilian population, NHANES estimated that approximately 2.7 million persons are chronically
infected with HCV and about 3.6 million people are acutely infected with HCV between 2003
and 2010 (4). Studies conducted earlier between 1988 and 1994 yielded a similar estimate of
the US population with CHI of 2.7 million persons (27) and 3.2 million persons had CHI between
1999 and 2002 (28). However, these numbers underestimate the true prevalence because
NHANES does not include institutionalized population, which is at a high-risk of HCV infection.
Edlin et al (29) conducted a systematic review of peer-reviewed literature and unpublished
presentations to estimate the prevalence of hepatitis C in the excluded populations in the US.
An estimated 1.0 million HCV antibody positive persons are excluded from the NHANES
sampling frame and 0.8 million are currently infected leading to a total of at least 4.6 million
with HCV antibody and 3.5 million currently infected.
Overall prevalence of cirrhosis in HCV-infected patients increased from 20.8% in 2006 to
27.6% in 2015 and overall prevalence of decompensated cirrhosis increased from 9.3% in 2006
to 10.4% in 2015 in HCV infected patients aged 60 or older (13). The high prevalence of HCV
and HCV mediated comorbidities in the US indicate the persistence of HCV infection since its
discovery in 1989 due to numerous reasons inclusive but not limited to higher rates of
treatment costs, undiagnosed and/or untreated infections and behavioral risk factors among
others.
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2.5 Risk Factors for HCV infection – Demographic and Behavioral risk factors
HCV infection in patients is primarily spread by blood contact. Intravenous drug injection is
the primary risk factor associated with new HCV infections. Therefore the three primary risk
groups are intravenous drug users, recipients of blood transfusion before 1992 and health care
workers (30). Since 1992, blood donors are routinely screened for HCV to eliminate HCV
infected blood in the process of blood transfusion. Alter et al (27) were the first to study
prevalence of HCV in the US using NHANES datasets by behavioral risk factors. In this study
conducted to estimate prevalence of HCV from 1988 – 1994, the authors determined that
illegal drug use and high-risk sexual behavior were the strongest risk factors independently
associated with HCV infection among participants 17 to 59 years of age. Increased prevalence
of HCV infection was associated with increasing number of times cocaine or marijuana was
used and highest prevalence of HCV infection was seen among persons who had 10 or more
sexual partners.
HCV seroprevalence has been reported in 75-90% of long-term (>3 years) injection drug
users (IDU) and in 18%-38% of short-term (<3 years) IDUs (31-33). It is also a known fact that
injection drug use is the strongest risk factor independently associated with HCV infection. For
example, the 1945-1965 birth cohort is an important predictor for anti-HCV positivity because
of high rates of injection drug use in this cohort termed the baby boomers’ cohort. In 2012, CDC
issued a recommendation to test all persons born in this cohort for HCV infection without prior
risk ascertainment (34). This was further supported by the findings from Smith et al (35) who
determined the prevalence and predictors of anti-HCV positivity among primary care
outpatients using risk-based testing that 74% of the identified anti-HCV positive patients were
born between 1945-1965. Anti-HCV positivity was significantly higher in these patients when
compared with the referent group of those born before 1945 or after 1965.
Patients undergoing hemodialysis are at a higher risk for HCV infection with a prevalence
estimate of 0.8% of HCV antibodies in the US (36). Prevalence in hemodialysis patients has been
found to increase with longer hemodialysis duration, male sex, black ethnicity, comorbidities
(example: diabetes, hepatitis B), prior kidney transplant, alcohol or drug abuse (37).
Demographic risk factors such as male sex, older age of 40-59 years, non-hispanic black, lesser
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than high school education and lower family income were determined to be significantly and
independently associated with HCV infection by Denniston et al (4).
2.6 Public health impact of examination of comprehensive behavioral risk factors for CHI
Various studies listed in this review have examined one or more of the risk factors
associated with HCV infection inclusive of demographic factors such as age 40-59 years, male
sex, lower family income, non-Hispanic black ethnicity, 1945-1965 birth cohort and behavioral
factors such as illegal drug use, alcohol use and >/= 10 life time sex-partners. Denniston et al (4)
conducted a comprehensive study by examination of the aforementioned demographic risk
factors, illicit drug use and receipt of blood transfusion before 1992 and determined that
persons aged 40-59 years, non-Hispanic black, less than high school education, illicit drug use
and receipt of blood transfusion before 1992 were significantly associated with CHI.
Comprehensive risk factor profile may include a combination of different types of illicit
drugs, injection drugs, alcohol use, smoking, and >10 lifetime sex-partners. Examination of
comprehensive profile of behavioral risk factors for CHI will help to refine identification of the
populations at risk for CHI, enabling screening, behavioral interventions, and linking them to
care and treatment. Up-to-date, an estimation of CHI prevalence using comprehensive
behavioral risk factor profile has not been published. In our study, we propose to estimate the
prevalence of CHI in the US non-institutionalized, civilian population using NHANES datasets
from 2003-2014. We will determine comprehensive behavioral risk factors associated with CHI,
which will improve identification of at risk populations to link them to optimal treatment, care,
prevention of comorbidities and reduce the associated health care costs. Estimates of CHI
burden are essential to guide policy and programs to optimally prevent, detect and treat the
infection. State-level estimates of the CHI prevalence are essential for developing intervention
programs, research, and federal assistance funding priorities among US states. Results from this
thesis will be critical to develop a prediction model for estimation of state-level prevalence of
CHI where less information on behavioral risk factors are available.
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CHAPTER THREE
METHODOLOGY
3.1 Data Source
We performed secondary data analyses using the Centers for Disease Control and
Prevention’s National Center for Health Statistics survey called NHANES. This survey collects
nationally representative data on the health and nutritional status of the U.S.
noninstitutionalized civilian population and is a public use dataset. In this study, we combined
data from several NHANES data sources including demographic information, laboratory testing
and questionnaire datasets from subjects interviewed between 2003-2014. NHANES provides
information on the non-institutionalized civilian resident population. It excludes persons in care
or custody of institutionalized settings, all active-duty military, all active- duty family members
living overseas, and US citizens living outside of the 50 states and District of Columbia (38).
3.2 Survey and Sample design
NHANES examines a nationally representative sample of about 5,000 persons each year
located in counties across the US. The NHANES interview includes demographic,
socioeconomic, dietary, and health-related questions. The examination component consists of
medical, dental, and physiological measurements, as well as laboratory tests administered by
highly trained medical personnel. Findings from the survey was used to determine the
prevalence of major diseases and risk factors for diseases.
A four-stage sample design was implemented in the datasets used in this study. The first
stage primary sampling units (PSUs) were selected from a frame of all U.S. counties; the
second-stage included a sample of area segments such as census blocks; the third-stage sample
selection consisted of dwelling units (DUs) such as noninstitutionalized group quarters and the
fourth stage consisted of persons within DUs or households (38).
3.3 Demographics Variables
Sample persons demographics data files for 2003-2004, 2005-2006, 2007-2008, 2009-2010,
2011-2012 and 2013-2014 were downloaded from the NHANES website for each cohort
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(https://wwwn.cdc.gov/Nchs/Nhanes/2003-2004/DEMO_C.htm). Following is the list of
demographic variables used in this study,
1. RIDAGEYR- Age and screening Adjudicated, categorical variable. This is the age of the
sample person at the time of the screening interview. From 1 through 84 years of age,
age of the sample person is reported by single year of age. Adults 85 years and older
have a value of 85. In this study, age categories were 0-19, 20-39, 40-59, 60 plus.
2. RIDRETH1- Race/Ethnicity. This categorical variable was derived from responses to the
survey questions on race and Hispanic origin. In this study, all other races except nonHispanic black were recoded into a ‘Other Races’ category.
3. RIAGENDR- Gender, categorical variable. Females were the referent group in adjusted
and unadjusted logistic regression models in this study.
4. DMDEDUC2- Education level, adults 20+, continuous variable. This variable is the highest
grade or level of education completed by adults 20 years and older. Range of value
descriptions are less than 9th grade, 9-11th grade, high school/ General Equivalency
Diploma (GED), some college or associate degree, college graduate or above. Response
categories were recoded into less than high school graduate/GED education and greater
than high school graduate/GED education.
5. DMDMARTL- Marital Status, categorical variable. Response categories in this variable
were recoded into i). Never married, ii). Widowed/Separated/Divorced and iii).
Married/Living with partner.
6. INDFMPIR- Family Poverty to Income Ratio, categorical variable. This variable is an index
for the ratio of family income to poverty. This variable was calculated by dividing family
income by the poverty guidelines specific to the family size, state and year. Response
values in this variable were recoded into i). < 2.0 times the family income to poverty
ratio and ii). >/= 2.0 times the family income to poverty ratio.
3.4 Behavioral Risk Factor Variables
Sample persons questionnaire data files for behavioral risk variables were downloaded from
respective cohorts from NHANES website
(https://wwwn.cdc.gov/nchs/nhanes/search/datapage.aspx?Component=Questionnaire&Cycle
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BeginYear=2005). Alcohol use, drug use, smoking and sexual behavior variables were the
behavioral risk variables while blood transfusion was the medical examination variable in this
study.
Blood Transfusion variable
I.

MCQ092: Ever receive blood transfusion

Alcohol variables
I.

Alq101: Had at least 12 alcohol drinks/year

II.

Alq110: Had at least 12 alcohol drinks/lifetime

III.

Alq130: Average number of alcoholic drinks/day in the past 12 months

Four alcohol categories were created by recoding the alcohol variables as follows (39),
•

Alcohol category 1: Lifetime abstainers < 12 drinks ever

•

Alcohol category 2: Former drinkers >/= 12 drinks in their lifetime but none in the past
year

•

•

Alcohol category 3: Non-excessive current drinkers on average reported
•

Male gender: </= 14 drinks/week

•

Female gender: </= 7 drinks/week

Alcohol category 4 = Excessive current drinkers reported
•

Male gender: > 14 drinks/week

•

Female gender: > 7 drinks/week

These were further condensed into two alcohol risk categories where alcohol categories 1,
2, 3 were classified as sample persons with no alcohol risk and alcohol category 4 was classified
as sample persons with alcohol risk.
Drug variables
For 2003-2004 cohort following variables were recoded into ever-inject variable in this study,
I.

Duq120: Ever used needle to take drugs

II.

Duq100: Ever used cocaine or other street drug
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Variables for use of marijuana or hashish, cocaine, heroin and methamphetamine were not
available for this cohort.
For 2005-2014 cohorts following variables were used which were recoded into variables as
indicated below,
I.

Duq200: Ever used marijuana or hashish which was recoded as evermarijuana

II.

Duq240: Ever used cocaine/heroin/methamphetamine

III.

Duq250: Ever used any form of cocaine along with duq240 were recoded as evercocaine

IV.

Duq290: Ever used heroin along with duq240 were recoded as heroin

V.

Duq330: Ever used methamphetamine along with duq240 were recoded as
evermethamphetamine

VI.

Duq370: Ever used needle to inject illegal drug was recoded as everinject

Smoking variable
I.

Smq020: Smoked at least 100 cigarettes in life was recoded as ever_smoked

Sexual behavior
For all cohorts, following variables were recoded into lifetime sex-partners (Table 1).
Table 1: Lifetime sex-partners variable and recode
Cohort

Variable name for

Variable name for

Variable recode into

number of female sex-

number of male sex-

lifetime sex-

partners/lifetime (A)

partners/lifetime (B)

partners

2003-2004

Sxq170

Sxq200

A+B

2005-2014

Sxq171

Sxq101

A+B

3.5 Laboratory Testing
Laboratory testing was carried out to detect anti-HCV in blood or serum using direct solidphase enzyme immunoassay (VITROS Anti-HCV Immunodiagnostic System, Ortho Clinical
Diagnostics, Rochester, New York). A confirmatory recombinant immunoblot assay (RIBA) (RIBA
26

HCV 3.0 Strip Immunoblot Assay, Emeryville, California) an in vitro qualitative immunoassay
was performed for the detection of anti-HCV in human blood or serum. Samples with positive
results on RIBA testing were confirmed as positive for anti-HCV, with negative results were
reported as confirmed negative for anti-HCV and those with indeterminate results were
reported as indeterminate.
Chronically infected persons are currently infected and it is important in clinical practice to
identify these persons. Serum samples that were confirmed positive or indeterminate for antiHCV were further tested for HCV RNA using COBAS AMPLICOR HCV Test, version 2.0 (Roche
Diagnostics, Indiana, US) an in-vitro nucleic acid amplification for HCV RNA on the COBAS
AMPLICOR Analyzer (Roche Diagnostics) for samples from 2003 to 2010, 2012-2014 and the
AMPLIPREP COBAS TaqMan HCV Test performed on the COBAS AMPLIPREP and COBAS
TaqMAN 48 Analyzer for samples from 2011-2012 (4).
Sample persons laboratory data files for HCV RNA were downloaded from respective
cohorts from the NHANES website
(https://wwwn.cdc.gov/nchs/nhanes/search/datapage.aspx?Component=Laboratory&CycleBeg
inYear=2003). For 2003-2004, SSHCVRNA was the HCV RNA variable. Exam sample weights were
used for the analysis of this cohort. For rest of the cohorts LBXHCR was the HCV RNA variable
used without the exam sample weights since it was not required.
I.

SSHCVRNA: Hepatitis C RNA

II.

LBXHCR: Hepatitis C RNA

3.6 Statistical Analyses:
SAS version 9.4 developed by the SAS Institute (NC, USA) a statistical package designed to
analyze complex survey data was used for all analyses in this study. Estimates were weighted to
represent the total U.S. noninstitutionalized civilian population, to account for oversampling
and nonresponse to the household interview and medical examination. Two-year sample
weights (WTMEC2R) were used for the weighted analyses. A p value less than 0.05 was
considered statistically significant.
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For descriptive statistics, to estimate the prevalence of CHI persons with demographic
characteristics such as age such as smoking, alcohol use, illegal drugs use (marijuana, cocaine,
methamphetamine, heroin and injection drugs), blood transfusion and number of lifetime sexpartners we have implemented bivariate analyses. We created an ordinal variable with the
number of risk factors - 0, 1, 2, 3, 4, 5, 6, 7 for calculation of risk factor scores for CHI.
We have conducted unadjusted and adjusted weighted multivariate logistic regression
analyses for determination of risk factors significantly associated with CHI in persons of age 20
to 59 years because data on drug use and sexual behaviors in persons < 20 years and >/= 60
years of age are not available from NHANES.
We have included and analyzed missing data cases as a separate domain rather than
excluding the data from the analyses because missing data is not always completely at random
and its inclusion accounts for the accurate analyses of the entire data sets. We have used the
Not Missing Completely at Random (NOMCAR) option in weighted logistic regression models to
include the missing data. The following groups were used as referent groups for the analysis
variables used in logistic regression models:
1. Age = 20-39 y
2. Sex = Female
3. Race/Ethnicity = All others except non-Hispanic black
4. Marital = Married, living with partner
5. Education= High school or more
6. Family income = >= 2.0 times poverty level
7. Smoking = Never smoked
8. Alcohol consumption = combined 3 groups (i.e., never drinkers, former drinkers, and
non-excessive current drinkers)
9. Marijuana = Never
10. Cocaine = Never
11. Heroin = Never
12. Methamphetamine = Never
13. Injection drug use (IDU) = Never
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14. Blood Transfusion = No
15. Lifetime Sex-partners = 0-1 lifetime sex-partners
For unadjusted and adjusted multivariate logistic regression analyses, we have pursued
three models to determine the association between risk factors and CHI. They are
1). Chronic HCV full model (Model 1) - In this model, we have included all the demographic and
behavioral risk factors mentioned in this study to assess the associations with CHI.
2). Chronic HCV risk factor model (Model 2)- In this model, we have included the demographic
variables, blood transfusion, number of CHI.
3). Chronic HCV Behavioral Risk Factor and Surveillance System (BRFSS) model (Model 3)BRFSS is the nation’s premier system of health-related telephone surveys that collect state data
about U.S. residents regarding their health-related risk behaviors, chronic health conditions and
use of preventive services (www.cdc.gov/brfss/index.html). In this model, we have included
only variables that are also available on the BRFSS. This includes the demographic variables,
alcohol use and smoking to assess the associations with CHI. In the future, the results of model
will be critical for developing a prediction model to estimate state-level prevalence of CHI.
The C-statistic (sometimes called the ‘concordance’ statistic or C-index) is a measure of
goodness of fit for binary outcomes in a logistic regression model. It is a standard measure of
the predictive accuracy of a logistic regression model (40). It is equal to the area under the
Receiver Operating Characteristic (ROC) curve and ranges from 0.5 to 1.
•

A value < 0.5 indicates a very poor model.

•

A value of 0.5 means that the model is no better than predicting an outcome by random
chance.

•

Values > 0.7 indicate a good model.

•

Values > 0.8 indicate a strong model.

•

A value of 1 means that the model perfectly predicts those group members who will
experience a certain outcome and those who will not.

We have compared the c-statistics between the three models in this study.
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CHAPTER FOUR
RESULTS
4.1 Estimated Prevalence of HCV RNA
The estimated number of HCV RNA-positive persons among of age 20-59 years in birth
cohorts 2003-2004, 2005-2006, 2007-2008, 2009-2020, 2011-2012, 2013-2014 were 2.56
million (95% CI, 1.75-3.36), 2.19 million (95% CI, 1.23-3.13), 2.68 million (95% CI, 1.71-3.64),
1.95 million (95% CI, 1.12-2.76), 2.08 million (95% CI, 0.95-3.19) and 1.92 million (95% CI, 1.412.43) respectively (Figure 2). Figure 2 shows that estimated number of CHI population has
decreased since 2008, but the differences were not statistically significant.
Figure 2: Weighted estimates of CHI persons of age 20-59 y from 2003-2014

Esdmated persons Infected, in millions

3.5
3
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2.56

2.5
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2.19

2.08
1.95

1.93

1.5

CHI posidve

1
0.5
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2003-2004 2005-2006 2007-2008 2009-2010 2011-2012 2013-2014

Cohort

Drug use, smoking and alcohol use were the substance abuse risk factors for CHI in this study.
Based on the number of substance abuse risk factors, we grouped these into three categories
as low (0-1), moderate (2-4) and high (5-7). Next, we estimated the prevalence of chronic HCV
RNA-positive persons by these three categories (Figure 3). Prevalence of CHI increased
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gradually from 0.2% at low to 1.1% at moderate risk, followed by a sharp increase to 11.0 % at
high-risk population.

Figure 3: Prevalence of chronic HCV by number of substance abuse risk factors, 2003-2014
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4.2 Crude associations of Demographic and Behavioral Risk Factors of persons with CHI
We have presented descriptive statistics on demographical and behavioral risk factors of
persons with CHI by bivariate analyses (Table 2). Age, race/ethnicity, education, marital status,
and family income were associated with HCV-RNA-positive status.
Participants of age 40-59 years had a CHI prevalence of 2.48% and more likely to be
infected, whereas CHI prevalence was 0.37 in 20-39 y age group. Non-Hispanic blacks had a CHI
prevalence of 2.25% when compared to 1.14% in other races. Male participants had a CHI
prevalence of 1.84% when compared to 0.96% in females. Participants with less than high
school education/GED had a CHI prevalence of 2.26% when compared to 1.11% in participants
who had high school education and above. Widowed/divorced/separated participants had the
highest CHI prevalence of 2.75% when compared to never married, married/living with partner
groups who had a CHI prevalence of 1.00% and 1.20% respectively. Participants who were at <
2.0 times poverty level had a CHI prevalence of 2.15% when compared to 0.76% in participants
who were at > 2.0 times poverty level.
Table 2: Demographic Characteristics by CHI status in participants of age 20-59 years, NHANES
2003-2014

Variable

Age, years

Race

Gender

Category

Sample Size

HCV RNA-

%HCV RNA-

Positive

positive

20-39

10,696

40

0.37

40-49

5,309

111

2.09

50-59

4,649

134

2.88

Non-Hispanic black

4397

99

2.25

Other races

16,257

186

1.14

Male

9,907

182

1.84
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Education

Female

10,747

103

0.96

Less than high

4,787

108

2.26

15,851

176

1.11

Never married

5,007

50

1.00

Widowed, divorced,

3,052

84

2.75

12,585

151

1.20

9,158

197

2.15

10,044

76

0.76

school education
High school
education and
above
Marital status

separated
Married, living with
partner
Family Income

< 2.0 times poverty
level
>/= 2.0 times
poverty level

Bivariate analysis of behavioral risk factors indicated that participants who smoked had a
CHI prevalence of 2.76% as compared to 0.33% among non-smokers. Participants who
consumed alcohol had a CHI prevalence of 1.71% and more likely to be infected when
compared to non-consumers of alcohol who had a 0.84% CHI prevalence. Participants who had
consumed marijuana, cocaine, methamphetamine, heroin had a CHI prevalence of 2.23%,
5.01%, 7.17% and 18.16% when compared to the CHI prevalence 0.4%, 0.55%, 0.93% and 0.94%
among non-consumers of marijuana, cocaine, methamphetamine and heroin respectively. IDU
participants had a CHI prevalence of 30.24% while non-injection drug users were 0.71% CHI
prevalent. Recipients of blood transfusion had a CHI prevalence of 2.47% as compared to 1.19%
in participants who were not recipients of blood transfusion. Participants who had >/= 10
lifetime sex-partners had a CHI prevalence of 2.63% as compared to 0.27% and 0.82% in other
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groups. Participants in high substance abuse risk factors category had a CHI prevalence of
11.11% as compared to 0.24% and 1.12% CHI prevalence in participants in low and moderate
categories (Table 3).
Table 3: Behavioral Risk Factors by CHI status in participants of age 20-59 years, NHANES
2003-2014
Variable

Ever smoked

Alcohol

Evermarijuana

Evercocaine

Evermethamphetamine

Everheroin

Everinject

Blood transfusion

Category

Sample Size

HCV RNA-

%HCV RNA-

Positive

positive

Yes

8,911

246

2.76

No

11,734

39

0.33

Yes

7,708

132

1.71

No

9,239

78

0.84

Yes

8,424

188

2.23

No

7,079

28

0.40

Yes

2,837

142

5.01

No

12,651

70

0.55

Yes

1,130

81

7.17

No

14,359

133

0.93

Yes

391

71

18.16

No

15,095

142

0.94

Yes

410

124

30.24

No

17,744

126

0.71

Yes

4,170

103

2.47

No

19,017

227

1.19

34

Lifetime sex-partners

Substance abuse risk

0-1

2,588

7

0.27

2 to 9

7,299

60

0.82

>/=10

5,066

133

2.63

Low (0-1)

7,072

17

0.24

Moderate

6,352

71

1.12

702

78

11.11

factors

(2,3,4)
High (5,6,7)
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4.3 Associations between risk factors and CHI adjusted for potential confounders
In this study, we have predicted associations between risk factors and CHI using three
models whose results are described below.
1). Model 1 - For adjusted weighted multivariate logistic regression analysis, demographic
and risk factor variables were adjusted for all variables in the model. Simple unadjusted
logistic regression indicated for participants of age 20-59 years found that age 40-59
years, male sex, non-Hispanic black, separated/divorced/widowed/living separately, less
than high school/GED education, family income less than twice the poverty level,
smoking, alcohol consumption, marijuana, cocaine, heroin use, use of injection drugs,
blood transfusion and having >/= 10 lifetime sex-partners were significantly associated
with CHI.
Adjusted logistic regression analysis for participants of age 20-59 years found that
participants with the following characteristics had significant associations with CHI,
indicating they had higher odds of an HCV infection when compared to their respective
referent groups (Table 4).
1. Age groups 40-49 y and 50-59 y had an odds ratio (OR) of 7.9 (95% CI, 3.8-16.2) and
8.0 (95% CI, 3.5-18.2) respectively
2. Non-Hispanic blacks had an OR of 2.4 (95% CI, 1.3-4.1) as compared to the referent
group
3. Less than high school/GED had an OR of 2.6 (95% CI, 1.5-4.8)
4. Family income at < 2.0 times poverty level had an OR of 3.5 (95% CI, 1.9-6.6)
5. Heroin consumers had an OR of 2.3 (95% CI, 1.1-4.6)
6. IDU had an OR of 8.1 (95% CI, 3.1-21)
7. Blood transfusion had an OR of 2.9 (95% CI, 1.4-5.7)
8. >/= 10 lifetime sex-partners had an OR of 5.5 (95% CI, 1.5-19.7)

Table 4: Model 1 - Unadjusted and adjusted odds ratios for the risk associated with CHI in
participants of age 20-59 years, NHANES 2003 – 2014 (n = 11,596).

Characteristic

Unadjusted

Adjusted

OR

95% CI

OR

95% CI

20-39 y

(ref)

(ref)

(ref)

(ref)

40-49 y

5.8

2.9-11.5

7.9

3.8-16.2

50-59 y

5.9

3.0-11.9

8.0

3.5-18.2

Male

2.8

1.6-4.9

2.3

0.9-5.5

Female

(ref)

(ref)

(ref)

(ref)

Non-Hispanic Black

2.4

1.5-3.8

2.4

1.3-4.1

Other races

(ref)

(ref)

(ref)

(ref)

Married, living with partner

(ref)

(ref)

(ref)

(ref)

Sep/Div/Wid/Liv Sep

2.7

1.5-4.7

1

0.4-2.1

Never married

1.2

0.7-2.3

1.2

0.5-2.7

Less than high school/GED

4.6

3.0-7.1

2.6

1.5-4.8

High school or more

(ref)

(ref)

(ref)

(ref)

Age at interview

Sex

Race/ethnicity

Marital

Highest education level

Family income
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< 2.0 times poverty level

4.6

2.8-7.8

3.5

1.9-6.6

>= 2.0 times poverty level

(ref)

(ref)

(ref)

(ref)

Yes

6.7

3.5-12.9

1.9

0.8-4.2

No

(ref)

(ref)

(ref)

(ref)

Yes

2.1

1.3-3.3

1.3

0.7-2.3

No

(ref)

(ref)

(ref)

(ref)

Yes

3.6

2.0-6.6

0.7

0.3-1.9

No

(ref)

(ref)

(ref)

(ref)

Yes

10.5

6.3-17.6

1.8

0.9-3.7

No

(ref)

(ref)

(ref)

(ref)

Yes

28.7

18.0-45.7

2.3

1.1-4.6

No

(ref)

(ref)

(ref)

(ref)

Yes

12

7.2-20.0

1.9

0.8-4.5

No

(ref)

(ref)

(ref)

(ref)

Yes

46

29.3-72

8.1

3.1-21

No

(ref)

(ref)

(ref)

(ref)

Smoking

Alcohol Consumption

Marijuana

Cocaine

Heroin

Methamphetamine

Injection drugs
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Blood transfusion
Yes

2.9

1.7-5.0

2.9

1.4-5.7

No

(ref)

(ref)

(ref)

(ref)

0-1

(ref)

(ref)

(ref)

(ref)

2-9

4.4

1.5-13

2.8

0.9-8.5

>/=10

22.4

7.7-65

5.5

1.5-19.7

Lifetime sex-partners
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2). Model 2- For adjusted weighted multivariate logistic regression analysis, number of
substance abuse risk factors were adjusted for cohort, age, race, gender, education, family
income, marital status, blood transfusion and number of lifetime sex-partners (Table 5). Simple
unadjusted and adjusted logistic regression indicated that having >/= 2 risk factors were
significantly associated with CHI. In the adjusted analysis, participants in moderate and high
categories had an OR of 2.5 (95% CI, 1.1-5.5 and 30.3 (95% CI, 12.1-76) respectively, indicating a
significant association with CHI when compared to the referent group.
Table 5: Model 2 - Unadjusted and adjusted odds ratios for the risk associated with CHI in
participants of age 20-59 years, NHANES 2003 – 2014 (n = 11,596).

Characteristic
Number of Drugs, Smoking

Unadjusted

Adjusted

OR

95% CI

OR

95% CI

Low (0-1)

(ref)

(ref)

(ref)

(ref)

Moderate (2-4)

4.5

2.1-9.54

2.5

1.1-5.5

High (5-7)

54.5

25.2-117.8

30.3

12.1-76

and alcohol
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3). Model 3 - For adjusted weighted multivariate logistic regression analysis, demographic and
risk factor variables were adjusted for all variables in the model (Table 6). Simple unadjusted
logistic regression for participants of age 20-59 years indicated that 20 – 59 years, male sex,
non-Hispanic black, separated/divorced/widowed/living separately, having less than high
school/GED education, family income less than twice the poverty level, alcohol consumption
and smoking were significantly associated with CHI.
In the adjusted analysis, participants with the following characteristics had significant
associations with CHI therefore indicating that they had higher odds of an HCV infection when
compared to their respective referent groups.
1. Age groups 40-49 y and 50-59 y had an odds ratio (OR) of 7.5 (95% CI, 3.5-15.9) and 8.7
(95% CI, 4.2-18).
2. Males had an OR of 3.1 (95% CI, 1.5-6.4)
3. Non-Hispanic blacks had an OR of 1.8 (95% CI, 1.1-2.9)
4. Less than high school/GED had an OR of 2.2 (95% CI, 1.3-3.8)
5. Family income < 2.0 times the poverty level had an OR of 3.7 (95% CI, 2.0-6.8)
6. Alcohol consumers had an OR of 1.7 (95% CI, 1.0-2.9) and
7. Smokers had an OR of 3.7 (95% CI, 1.8-7.6)

41

Table 6: Model 3 - Unadjusted and adjusted odds ratios for the risk associated with CHI in
participants of age 20-59 years, NHANES 2003 – 2014 (n = 11,596).
Characteristic

Unadjusted

Adjusted

OR

95% CI

OR

95% CI

20-39 y

(ref)

(ref)

(ref)

(ref)

40-49 y

5.8

2.9-11.5

7.5

3.5-15.9

50-59 y

6

3.0-11.9

8.7

4.2-18

Male

2.8

1.7-4.9

3.1

1.5-6.4

Female

(ref)

(ref)

(ref)

(ref)

Non-Hispanic Black

2.3

1.5-3.8

1.8

1.1-2.9

Other races

(ref)

(ref)

(ref)

(ref)

(ref)

(ref)

(ref)

(ref)

Sep/Div/Wid/Liv Sep

2.7

1.5-4.7

1.4

0.7-2.8

Never married

1.2

0.7-2.3

1.4

0.7-2.9

4.6

3.0-7.1

2.2

1.3-3.8

(ref)

(ref)

(ref)

(ref)

4.6

2.8-7.8

3.7

2.0-6.8

(ref)

(ref)

(ref)

(ref)

Age at interview

Sex

Race/ethnicity

Marital
Married, living with
partner

Highest education
level
Less than high
school/GED
High school or more
Family Income
<2.0 times poverty
level
>= 2.0 times poverty
level
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Alcohol
Consumption
Yes

2.1

1.3-3.3

1.7

1.0-2.9

No

(ref)

(ref)

(ref)

(ref)

Yes

6.7

3.5-12.9

3.7

1.8-7.6

No

(ref)

(ref)

(ref)

(ref)

Smoking

4.4 C-statistic- C-statistic of the models 1, 2 and 3 were 0.94, 0.92 and 0.88 respectively
indicating that all three models were strong models with a higher predictive accuracy of CHI in
persons strongly associated with respective demographic and behavioral risk factor variables in
the models.
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CHAPTER FIVE
DISCUSSION AND CONCLUSIONS
DISCUSSION
The primary purpose of this study was complex examination of the NHANES datasets from
2003-2014 to assess combination of demographical and behavioral risk factors associated with
CHI in the general U.S. population. The NHANES survey provides important information as it
comprises the nationally representative sample of the US non-institutionalized population. The
standardization of its methods allows for consistent and good quality data collection (41). This
is the first study of its kind to use a complex data set of 6 cohorts from 2003 through 2014 for
examination of all possible risk factors (demographical + behavioral) significantly associated
with CHI in the adult US population 20-59 years of age using 3 models.
As of 2014, we estimated 1.93 million CHI persons in the general U.S. population of age 2059 years with a prevalence of 0.7% sampled by NHANES. This has slightly declined since 2010
based on Denniston et al estimation of 2.7 million as CHI infected persons from 2003-2010 in
the general U.S. population (4). As indicated in their study, our analysis also suggests that
declining prevalence of CHI in the noninstitutionalized U.S. population may likely be because of
increasing mortality from HCV-related conditions (42). This prevalence is an underestimation of
the true CHI population in the US because NHANES does not include high-risk populations
including the incarcerated, hemodialysis patients, the homeless and people living on Indian
reservations, all active military and U.S. citizens living outside the U.S.A.
In this study, substance abuse risk factors such as drug use, alcohol consumption and
smoking were grouped into low (0-1), moderate (2-4) and high (5-7) summary risk factor score
categories based on the number of risk factors. In the absence of categorization of the
summary risk factor scores, fewer number of CHI observations were observed in each summary
risk factor score that resulted in wider confidence intervals. Thus, categorization helped to
overcome this concern. We have estimated the prevalence of CHI in these categories and found
a linear increase in CHI prevalence with increasing number of substance abuse risk factors
(Figure: 3) with a maximum of 11% CHI prevalence in persons pf the high category. This is the
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first study of its kind to estimate the CHI prevalence in persons associated with one or more
substance abuse risk factors.
Higher prevalence of CHI was seen in participants with the following socio-demographic
characteristics- 40-59 years, non-Hispanic black, male sex, less than high school education,
widowed/divorced/separated and family income less than 2.0 times poverty level when
compared to their respective control groups (Table 2). One or more of these observations were
also reported in earlier studies (4, 28, 41). The Centers for Disease Control and Prevention and
US Preventive Services Task Force have recommended 1-time HCV screening in persons born
between 1945-1965 (43, 44) which corresponds to age 49-69 in the year 2014 and account for
most of the prevalent HCV cases. Table 3 in this study noticeably shows that the age groups 4049 and 50-59 had a prevalence of 2.09% and 2.88% respectively with a total prevalence of
4.97% contributing to 93% of the infected population in 20-59 years of age. Results from our
study supports the findings from earlier studies (4, 41).
Higher prevalence of CHI was seen in participants with the following behavioral risk
characteristics- smoking, alcohol consumption, consumption of marijuana, cocaine,
methamphetamine, heroin, injection drug users, blood transfusion recipients prior to 1992 and
>/=10 life time sex-partners when compared to their respective referent groups (Table 3).
Denniston et al (4) in their study have determined higher prevalence of CHI in participants of
age 60 and older who had received blood transfusion before 1992, in injection drug users, and
with 20-49 life time sexual partners when compared to their respective referent groups. Taylor
et al (39) have indicated higher prevalence of CHI in participants who were former drinkers and
excessive current drinkers when compared to non-drinkers. Results from these studies are in
line with some of the observations we have seen in our study although our study is unique
because we have estimated CHI prevalence in population who are smokers, consumers of
heroin, cocaine and methamphetamine that have not been determined in previous studies.
Knowledge of risk factors for CHI is important for several reasons not limited to 1).
Identification of at-risk populations to link to treatment and care 2). Resource allocation for
prevention measures and 3). To propose policy and guidelines for control and prevention of
CHI. This study is the largest and most comprehensive so far where the multivariate models
45

have included the most established confounders. This study is also the first of its kind to have
determined the risk factors associated with CHI by three models. As reported in a previous
study (4), the chronic HCV full model (Table 4) elicited that age 40-59 years, non-Hispanic
blacks, less than high school/GED, < 2.0 times poverty level were significantly associated with
CHI. Additionally, the chronic HCV full model has also established significant associations of
heroin consumption, blood transfusion and >/=10 lifetime sex-partners with CHI that have not
been reported earlier. IDU remains the strongest risk factor for CHI as reported earlier (4)
however in the earlier study IDU was combined with other drugs as a risk factor. For IDU
association with CHI, Denniston et al (4) have reported an OR of 8.7 whereas we have reported
an OR of 8.1, therefore showing that in both the studies the OR in the multivariate model is
similar. Race, low socioeconomic status and less education were associated with CHI because
these factors are often associated with high-risk behaviors and hence higher risk of infection.
Chronic HCV risk factor model undoubtedly shows that the OR increases with increasing
number of risk factors in a person. This is the first study where the number of substance abuse
risk factors (alcohol consumption, smoking and drug use) were categorized into low, moderate
and high-risk categories to determine the odds of being positive for CHI (Table 4). This data will
be crucial in identification of the positively infected population, link them to treatment, and
care before they become susceptible to secondary conditions such as hepatocarcinoma and
cirrhosis thereby reducing the HCV burden and its associated healthcare costs. Missing values in
the druq use questions in NHANES may not be equally distributed between the different socioeconomic status (SES) groups, which can lead to the biases in prevalence estimation and/or risk
factor estimation.
BRFSS datasets does not contain questions on risk factor variables such as drug use including
IDU and number of lifetime sex-partners. We carried out the third and final model to establish a
prediction model for the state level estimates of CHI including only alcohol and smoking risk
factor variables, which are available in BRFSS. In the absence of other potential confounders
used in model 1, alcohol consumption and smoking were significantly associated with CHI
(Table 6). The assumption that all states have the national level prevalence of CHI may yield
inaccurate state-specific estimates because risk of CHI more than likely varies by state.
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Therefore, model 3 is important because it may be duplicated to calculate state level estimates
such as BRFSS datasets and to determine the state level prevalence of CHI.
The values of C-statistic for the three models in this study were 0.94, 0.92 and 0.88
respectively. Such high c-statistic values indicate stronger models with higher predictive
accuracy of CHI in persons with associated demographic and risk factor variables in respective
models. Even with the limited number of risk factors modeled after the BRFSS datasets, cstatistic is 0.88 indicating good prediction of the model. Thus, our data can serve as validation
of the model based on BRFSS datasets.
Our study comes with several limitations as stated below,
1. We did not include participants of ages >/= 60 years due to the time and resource
limitations for conducting this thesis study. This limits us from comparing the prevalence
estimates and associations with CHI in this age group (minus the drug questions and lifetime sex-partner questions which are not asked for this population by NHANES) to the
results in previously published studies (4).
2. Since NHANES does not ask drug and lifetime sex-partner questions in adults of age >/=
60, we do not know the total true estimates of CHI prevalence and risk factor
associations in adults inclusive >/= 60 years. In future, it will be useful to conduct similar
studies in the baby boomers’ cohort who are 49-69 years of age in 2014 because this
cohort by itself is an important risk factor for CHI.
3. We did not present anti-HCV data in this study due to the time and resource limitations
in performing the thesis work. National level anti-HCV prevalence estimates and its risk
factor associations will enable to understand the larger picture of the CHI such as the
conversion of the number of acute HCV cases into chronic HCV cases.
4. As mentioned in earlier studies (4, 29, 41), results from NHANES data are only
applicable to the non-institutionalized U.S. civilian population, which underestimates
the true prevalence of CHI because of the exclusion of incarcerated, homeless and
institutionalized population in the datasets. Results from this thesis cannot be
extrapolated to the aforementioned high-risk groups for whom the prevalence of CHI is
likely to be higher.
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5. Questionnaire data is relied on self-reporting and therefore subject to recall bias. Use of
IDU and other drugs, having >/= 10 lifetime sex-partners are socially stigmatized
activities which may result in participants being unwilling to admit to this behavior
resulting in an underestimation of these factors in CHI prevalence and risk factor
associations.
CONCLUSIONS
We conclude that the estimated persons infected with CHI as of 2014 is approximately 2.2
million in the civilian non-institutionalized U.S population sampled by NHANES. It has somewhat
declined since 2010 which may be because of HCV related mortality, however the true
prevalence estimates of CHI will be significantly higher when incarcerated, homeless and other
population excluded from NHANES are included in the analysis. Injection drug use continues to
be the strongest risk factor for CHI. Persons with two or more substance abuse risk factors have
the highest odds of getting CHI. Results from this study will be critical in development of public
health policies and guidelines for the identification of underappreciated CHI population and
linking them to appropriate treatment and care.
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